关于 2025 年第四季度可转换公司债券转股情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1、"花园转债"（债券代码：123178）转股期限为2023年9月11日至2029年3月5日； 最新的转股价格为人民币13.45元/股。 2、2025年第四季度，共有10张"花园转债"完成转股（票面金额共计人民币1,000.00 元），合计转成74股"花园生物"股票（证券代码：300401）。 3、截至2025年第四季度末，"花园转债"剩余债券张数为11,759,893张，剩余票 面总额为人民币1,175,989,300.00元。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自律监 管指引第15号——可转换公司债券》的有关规定，浙江花园生物医药股份有限公司（以 下简称"公司"）现将2025年第四季度可转换公司债券（以下简称"可转债"）转股及 公司股份变化情况公告如下： | 证券代码：300401 | 证券简称：花园生物 公告编号：2026-001 | | --- | --- | | 债券代码：123178 | 债券简称：花 ...

1. Report Industry Investment Rating No relevant content provided. 2. Report's Core View The report presents the top ten convertible bonds in January 2026, including their credit ratings, closing prices at the end of December, conversion premium rates, and the trailing twelve - month price - to - earnings ratios (PE - TTM) of their underlying stocks. It also details the business profiles, financial performance, and key highlights of the companies corresponding to these convertible bonds [2][4][6]. 3. Summary by Company 3.1 Zhongte Convertible Bond - **Company Overview**: A globally leading specialized special - steel material manufacturer with an annual production capacity of about 20 million tons of special - steel materials. It has multiple production and raw - material bases, forming a coastal and riverside industrial chain layout [11]. - **Financial Performance**: In 2024, its operating income was 109.203 billion yuan (YoY - 4.22%), net profit attributable to the parent company was 5.126 billion yuan (YoY - 10.41%). In the first three quarters of 2025, operating income was 81.206 billion yuan (YoY - 2.75%), and net profit attributable to the parent company was 4.33 billion yuan (YoY + 12.88%) [11]. - **Company Highlights**: It is one of the world's most comprehensive special - steel enterprises in terms of variety and specification. It has a complete industrial chain, leading cost - control ability, and is seeking external expansion opportunities [12]. 3.2 Shanlu Convertible Bond - **Company Overview**: Focuses on road and bridge engineering construction and maintenance, and is expanding into other fields. It has a complete business and management system [29]. - **Financial Performance**: In 2024, its operating income was 71.348 billion yuan (YoY - 2.3%), net profit attributable to the parent company was 2.322 billion yuan (YoY + 1.47%). In the first three quarters of 2025, operating income was 41.354 billion yuan (YoY - 3.11%), and net profit attributable to the parent company was 1.41 billion yuan (YoY - 3.27%) [29]. - **Company Highlights**: It has the concept of China - specific valuation, potential for improvement in balance sheet and orders, benefits from regional infrastructure plans, and is exploring overseas markets [30]. 3.3 Hebang Convertible Bond - **Company Overview**: Has advantages in resource supply and has completed a basic layout in the chemical, agricultural, and photovoltaic fields, with four major business segments [44]. - **Financial Performance**: In 2024, its operating income was 8.547 billion yuan (YoY - 3.13%), net profit attributable to the parent company was 31 million yuan (YoY - 97.55%). In the first three quarters of 2025, operating income was 5.927 billion yuan (YoY - 13.02%), and net profit attributable to the parent company was 93 million yuan (YoY - 57.93%) [44]. - **Company Highlights**: Its phosphate mines and salt mines contribute profits, and its liquid methionine production is a major profit - contributor [45]. 3.4 Huayuan Convertible Bond - **Company Overview**: Focuses on building a complete vitamin D3 upstream - downstream industrial chain, with products in the vitamin and chemical - preparation fields [56]. - **Financial Performance**: In 2024, its operating income was 1.243 billion yuan (YoY + 13.58%), net profit attributable to the parent company was 309 million yuan (YoY + 60.76%). In the first three quarters of 2025, operating income was 936 million yuan (YoY - 0.2%), and net profit attributable to the parent company was 234 million yuan (YoY - 3.07%) [56]. - **Company Highlights**: It has leading products in the market, is expanding its product matrix, and has a strong layout in the pharmaceutical manufacturing field [57]. 3.5 Xingye Convertible Bond - **Company Overview**: One of the first joint - stock commercial banks in China, evolving into a modern financial service group with multiple financial licenses [70]. - **Financial Performance**: In 2024, its operating income was 212.226 billion yuan (YoY + 0.66%), net profit attributable to the parent company was 77.205 billion yuan (YoY + 0.12%). In the first three quarters of 2025, operating income was 161.234 billion yuan (YoY - 1.82%), and net profit attributable to the parent company was 63.083 billion yuan (YoY + 0.12%) [70]. - **Company Highlights**: It has stable asset quality and scale growth, with a large number of customers [71]. 3.6 Aima Convertible Bond - **Company Overview**: The leading enterprise in the electric two - wheeled vehicle industry, producing and selling electric bicycles, scooters, and motorcycles [80]. - **Financial Performance**: In 2024, its operating income was 21.606 billion yuan (YoY + 2.71%), net profit attributable to the parent company was 1.988 billion yuan (YoY + 5.68%). In the first three quarters of 2025, operating income was 21.093 billion yuan (YoY + 20.78%), and net profit attributable to the parent company was 1.907 billion yuan (YoY + 22.78%) [80]. - **Company Highlights**: It may benefit from government subsidies, new national standards, and has potential for improving gross margins [81]. 3.7 Chongyin Convertible Bond - **Company Overview**: The earliest local joint - stock commercial bank in the upper reaches of the Yangtze River and Southwest China, listed on the Hong Kong Stock Exchange and included in the "Leading Sheep" plan [90]. - **Financial Performance**: In 2024, its operating income was 13.679 billion yuan (YoY + 3.54%), net profit attributable to the parent company was 5.117 billion yuan (YoY + 3.8%). In the first three quarters of 2025, operating income was 11.74 billion yuan (YoY + 10.4%), and net profit attributable to the parent company was 4.879 billion yuan (YoY + 10.19%) [90]. - **Company Highlights**: It benefits from the regional economic development, has stable asset - scale growth, and actively adjusts its business strategies [91][94]. 3.8 Tianye Convertible Bond - **Company Overview**: The first industrial enterprise of the Xinjiang Production and Construction Corps, a leading enterprise in the chlor - alkali chemical industry with an integrated circular economy industrial chain [103]. - **Financial Performance**: In 2024, its operating income was 11.156 billion yuan (YoY - 2.7%), net profit attributable to the parent company was 68 million yuan (YoY + 108.83%). In the first three quarters of 2025, operating income was 7.97 billion yuan (YoY + 2.2%), and net profit attributable to the parent company was 7 million yuan (YoY - 28.79%) [103]. - **Company Highlights**: It has cost - advantage in caustic soda production and plans to increase dividend frequency and has coal - mine projects in progress [106]. 3.9 Aorui Convertible Bond - **Company Overview**: A company focusing on the R & D, production, and sales of complex APIs and preparations, leading in several technical fields [119]. - **Financial Performance**: In 2024, its operating income was 1.476 billion yuan (YoY + 16.89%), net profit attributable to the parent company was 355 million yuan (YoY + 22.59%). In the first three quarters of 2025, operating income was 1.237 billion yuan (YoY + 13.67%), and net profit attributable to the parent company was 354 million yuan (YoY + 24.58%) [119]. - **Company Highlights**: It is optimizing its distribution network, expanding its overseas market for preparations, and has high - quality customer resources [120]. 3.10 Yushui Convertible Bond - **Company Overview**: The largest water supply and drainage integrated enterprise in Chongqing, with a monopoly position in the local market [133]. - **Financial Performance**: In 2024, its operating income was 6.999 billion yuan (YoY - 3.52%), net profit attributable to the parent company was 785 million yuan (YoY - 27.88%). In the first three quarters of 2025, operating income was 5.568 billion yuan (YoY + 7.21%), and net profit attributable to the parent company was 779 million yuan (YoY + 7.1%) [133]. - **Company Highlights**: It has a high market share, is expanding its business regionally, and has achieved cost control through intelligent applications [134].

| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、本次股东会无否决议案的情形； 2、本次股东会不涉及变更前次股东会决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 5、现场会议主持人：公司董事长邵徐君先生 6、股权登记日：2025年12月24日 现场会议召开时间：2025年12月31日（星期三）下午14:30。 网络投票时间：2025年12月31日。其中，通过深圳证券交易所交易系统进行网络投 票的时间为2025年12月31日上午9:15-9:25、9:30-11:30，下午13:00-15:00；通过深圳 证券交易所互联网投票系统进行投票的具体时间为2025年12月31日9:15-15:00的任意 时间。 2、现场会议地点：浙江省东阳市南马镇花园村花园大厦1号会议室。 7、会议的 ...

北京浩天律师事务所 关于浙江花园生物医药股份有限公司 "花园转债"2025 年第二次债券持有人会议 法律意见书 二〇二五年十二月三十一日 北京浩天律师事务所 法律意见书 北 京 浩 天 律 师 事 务 所 Hylands Law Firm 北京浩天律师事务所（以下简称"本所"）接受浙江花园生物医药股份有限公 司（以下简称"公司"）委托，指派本所律师对公司"花园转债"2025 年第二次债 券持有人会议（以下简称"本次会议"）进行法律见证，并依据《中华人民共和国 公司法（2023 年修订）》（以下简称《公司法》）、《中华人民共和国证券法（2019 年修订）》（以下简称《证券法》）、《可转换公司债券管理办法（2025 年修正）》 （以下简称《管理办法》）等法律、行政法规、规章、规范性文件以及公司的《创 业板向不特定对象发行可转换公司债券募集说明书》（以下简称《募集说明书》）、 《可转换公司债券持有人会议规则 》（以下简称《债券持有人会议规则》）的有 关规定，就公司本次会议的召集和召开程序、出席会议人员的资格和召集人资格、 会议的表决程序和表决结果等有关事宜出具法律意见。 北京市朝阳区东三环中路 5 号财富金融中心 ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2025-051 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 "花园转债"2025年第二次债券持有人会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏 浙江花园生物医药股份有限公司（以下简称"公司"）根据《公司向不特定对象 发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）、《公司可转换 公司债券持有人会议规则》（以下简称"《债券持有人会议规则》"）等相关规定， 于2025年12月31日召开"花园转债"2025年第二次债券持有人会议（以下简称"本次 债券持有人会议"）。本次债券持有人会议决议如下： 一、召开会议的基本情况 （一）会议召开情况 1、会议届次：2025年第二次债券持有人会议 2、会议召集人：公司董事会 3、会议主持人：公司董事长邵徐君 4、会议召开的合法、合规性：本次债券持有人会议的召开符合相关法律、行政 法规、部门规章、规范性文件和公司《募集说明书》《债券持有人会议规则》的规定。 5、会议召开的日期、 ...

北 京 浩 天 律 师 事 务 所 Hylands Law Firm 北京市朝阳区东三环中路 5 号财富金融中心 12 层 北京浩天律师事务所 关于浙江花园生物医药股份有限公司 2025 年第二次临时股东会 法律意见书 二〇二五年十二月三十一日 北京浩天律师事务所 浙江花园生物医药股份有限公司 2025 年第二次临时股东会法律意见书 12F Fortune Financial Center, No.5 Dongsanhuan Zhong Road, Chaoyang District, Beijing 100020, China 电话Tel：（86-10）65028888，传真Fax：（86-10）65028866 北京浩天律师事务所 关于浙江花园生物医药股份有限公司 2025 年第二次临时股东会 法律意见书 致：浙江花园生物医药股份有限公司 北京浩天律师事务所（以下简称"本所"）接受浙江花园生物医药股份有限 公司（以下简称"公司"）委托，指派本所律师对公司 2025 年第二次临时股东 会（以下简称"本次股东会"）进行法律见证，并依据《中华人民共和国证券法 （2019 年修订）》(以下简称《证券法》)、《中华 ...

2 | （五）募集资金使用 | | | | | --- | --- | --- | --- | | 现场检查手段：查阅、复制、检查、访谈 | | | | | 1.是否在募集资金到位后一个月内签订三方监管协议 | √ | | | | 2.募集资金三方监管协议是否有效执行 | √ | | | | 3.募集资金是否不存在第三方占用、委托理财等情形 | √ | | | | 4.是否不存在未履行审议程序擅自变更募集资金用途、暂时 | √ | | | | 补充流动资金、置换预先投入、改变实施地点等情形 | | | | | 5.使用闲置募集资金暂时补充流动资金、将募集资金投向变 | | | | | 更为永久性补充流动资金或者使用超募资金补充流动资金或 | | | √ | | 者偿还银行贷款的，公司是否未在承诺期间进行风险投资 | | | | | 6.募集资金使用与已披露情况是否一致，项目进度、投资效 | √ | | | | 益是否与招股说明书等相符 | | | | | 7.募集资金项目实施过程中是否不存在重大风险 | √ | | | | （六）业绩情况 | | | | | 现场检查手段：查阅、复制、检查、访谈 | | | ...

国联民生证券承销保荐有限公司 关于浙江花园生物医药股份有限公司 2025 年度持续督导培训情况的报告 1 （此页无正文，为《国联民生证券承销保荐有限公司关于浙江花园生物医药股份 有限公司 2025 年度持续督导培训情况的报告》之签章页） 保荐代表人： 本次培训通过演示培训讲义、解读法规条文及案例分析等形式进行，重点对 2025 年修订的法律法规如上市公司治理准则、上市公司募集资金监管规则等及 近年来典型违规处罚案例等方面进行了阐述分析。 二、培训对象 花园生物接受培训的人员为公司的实际控制人、控股股东、董事、高级管理 人员及其他相关人员。 三、培训效果 保荐机构认为，通过本次培训，上述人员增强了对 2025 年新规的认识，加 强理解作为上市公司管理人员在公司信息披露、规范运作等方面所应承担的责任 和义务，进一步提升公司的规范运作水平。本次培训达到了预期的效果。 （以下无正文） 根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监 管指引第 13 号——保荐业务》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》《深圳证券交易所创业板股票上市规则》等有关 规定的要求，作为 ...

证券日报网讯 12月25日，花园生物在互动平台回答投资者提问时表示，截至2025年12月19日，公司股 东总户数为29923户。 （文章来源：证券日报） ...

证券日报网讯12月17日，花园生物（300401）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东总户数为28320户。 ...